1.2 Reference Intervals, Critical Values & Specimen Integrity

1.2 Reference Intervals, Critical Values & Specimen Integrity

[!NOTE] Diagnostic Accuracy Foundation: An analytical result generated by an automated clinical chemistry analyzer is only as reliable as the integrity of the specimen submitted. Published error-frequency studies from stat and general clinical laboratories (Plebani and Carraro) attribute roughly 62% to 68% of all laboratory errors to the pre-analytical phase, far outstripping analytical and post-analytical error rates. Recognizing compromised specimens and understanding chemical interference mechanisms are essential core competencies for the C(ASCP) technologist.

---

Pre-Analytical Variables and Total Quality Management

The total testing process is classically divided into three distinct phases:

1. Pre-Analytical Phase: Test ordering, patient preparation, phlebotomy technique, collection tube selection, order of draw, specimen labeling, transport conditions, centrifugation, and aliquot handling.
2. Analytical Phase: Instrument calibration, quality control verification, reagent stability, automated pipetting, incubation, detection, and calculation.
3. Post-Analytical Phase: Verification, delta checking, critical value reporting, clinician notification, and clinical data interpretation.

Key Pre-Analytical Patient Variables

• Fasting Status: Failure to maintain an 8 to 12-hour fast elevates fasting glucose, triglycerides, and alkaline phosphatase (especially in intestinal secretors of blood groups O and B). Mild lipemia can interfere with optical testing.
• Diurnal Variation: Significant circadian fluctuations alter plasma concentrations throughout the 24-hour cycle. Serum cortisol peaks between 06:00 and 08:00 and reaches its nadir near midnight; Adrenocorticotropic Hormone (ACTH), serum iron, and testosterone exhibit similar morning peaks. Conversely, thyroid-stimulating hormone (TSH) peaks in the late evening/early morning.
• Posture and Position: Shifting from a supine to an upright (standing or sitting) position causes hydrostatic pooling of plasma water into the interstitial fluid space, reducing effective plasma volume by 8% to 10%. This hemoconcentration falsely elevates the apparent concentration of non-diffusible macromolecules and protein-bound substances by 5% to 15%, including albumin, total protein, enzymes (ALT, AST, ALP), cholesterol, triglycerides, and protein-bound calcium.
• Prolonged Tourniquet Stasis: Application of a tourniquet for greater than 1 minute causes localized venous stasis, fluid extravasation into surrounding tissue, and local tissue hypoxia. This produces localized hemoconcentration (elevating total protein, albumin, and calcium) and anaerobic glycolysis with intracellular potassium release and lactic acid accumulation.
• Strenuous Physical Exercise: Strenuous exercise induces transient muscular breakdown and metabolic shifts, resulting in sharp elevations in creatine kinase (CK), lactate dehydrogenase (LD), AST, myoglobin, blood lactate, and creatinine.

---

CLSI Standardized Order of Draw and Anticoagulant Tube Chemistry

To eliminate cross-contamination of tube additives between collection containers during multi-tube evacuated tube system (ETS) venipuncture, the Clinical and Laboratory Standards Institute (CLSI GP41, 7th edition — the standard formerly numbered H3-A6) mandates a strict Order of Draw.

+-----------------------------------------------------------------------------------------+
|                          CLSI GP41 Standardized Order of Draw                           |
+-----------------------------------------------------------------------------------------+
|  1. Blood Cultures (Yellow SPS / Culture Bottles) ──> Prevents bacterial contamination   |
|  2. Sodium Citrate (Light Blue Top) ───────────────> 3.2% Citrate; 9:1 blood ratio       |
|  3. Serum Tubes (Red Top / Gold SST) ──────────────> Clot activator / polymer barrier    |
|  4. Heparin (Green Top / PST) ─────────────────────> Lithium or Sodium Heparin           |
|  5. EDTA (Lavender / Pink Top) ────────────────────> K2EDTA or K3EDTA divalent chelator   |
|  6. Sodium Fluoride / Potassium Oxalate (Gray Top) > Antiglycolytic enolase inhibitor    |
+-----------------------------------------------------------------------------------------+

Tube Types, Additives, and Clinical Chemistry Applications

The Catastrophic Impact of EDTA Carryover

When blood is collected out of order—specifically drawing a lavender-top EDTA tube before a green-top heparin or red-top serum tube—or when blood is transferred from an EDTA tube using a syringe, catastrophic analytical interference occurs:

1. Severe Pseudohyperkalemia: Potassium EDTA carries significant concentrations of potassium salts (K+ additive), falsely elevating serum/plasma potassium to life-threatening panic levels (e.g., >8.0 mmol/L).
2. Profound Pseudohypocalcemia: EDTA avidly chelates free divalent calcium ions (Ca2+), reducing measurable total and ionized calcium to near-zero levels (<4.0 mg/dL).
3. Pseudohypomagnesemia: EDTA similarly chelates magnesium ions (Mg2+), producing artifactual hypomagnesemia.
4. Inactivation of Alkaline Phosphatase (ALP): Alkaline phosphatase is a metalloenzyme that requires structural magnesium (Mg2+) and zinc (Zn2+) cofactors for catalytic activity. Chelation of these ions by EDTA strips the active site, resulting in near-total enzymatic inhibition and an unmeasurably low or zero ALP result.

---

Mechanisms of Analytical Interference: Hemolysis, Icterus, and Lipemia (HIL)

Automated clinical chemistry analyzers utilize multi-wavelength spectrophotometry to quantify the HIL indices (Hemolysis, Icterus, Lipemia) directly on patient serum or plasma prior to performing scheduled photometric or electrochemical assays.

+-----------------------------------------------------------------------------------------+
|                    HIL Optical Absorbance Spectrum Characteristics                      |
+-----------------------------------------------------------------------------------------+
| Interferent      Primary Absorbance Peaks         Typical Measuring Wavelengths        |
+-----------------------------------------------------------------------------------------+
| Hemolysis (Hb)   Soret band ~415 nm; 540, 575 nm  Bichromatic ~540 nm / 575 nm          |
| Icterus (Bili)   Broad peak 400 nm - 500 nm       Bichromatic ~450 nm / 480 nm          |
| Lipemia (Turb)   Light scattering across spectrum Bichromatic ~660 nm / 700 nm          |
+-----------------------------------------------------------------------------------------+

1. Hemolysis

Hemolysis is defined as the disruption of erythrocyte membranes resulting in the release of intracellular hemoglobin and cellular constituents into the surrounding serum or plasma. It represents the single most common cause of specimen rejection in clinical chemistry laboratories.

Intracellular Release Mechanisms

The intracellular concentration of several key analytes within red blood cells vastly exceeds their concentration in normal extracellular plasma:

• Potassium (K+): Erythrocytes maintain an intracellular potassium concentration of approximately 105 to 110 mmol/L, compared to normal plasma levels of 3.5 to 5.0 mmol/L—a concentration gradient of roughly 25:1 to 30:1. Even slight, invisible in vitro hemolysis (free hemoglobin <0.5 g/L or 50 mg/dL) releases sufficient potassium to shift a normal value into a dangerous hyperkalemic range.
• Lactate Dehydrogenase (LD / LDH): Red blood cells contain approximately 150 to 200 times the LD activity found in normal serum, predominantly as the LD-1 and LD-2 isoenzymes. LD is the single most sensitive indicator of hemolysis; slight lysis produces massive false elevations.
• Aspartate Aminotransferase (AST): Erythrocytes contain roughly 40 to 80 times higher AST activity than serum. Alanine aminotransferase (ALT), by contrast, is present in erythrocytes in minimal quantities (intracellular-to-extracellular ratio <5:1). Hemolysis therefore generates an artificial, striking dissociation between AST and ALT, with isolated AST elevation.
• Magnesium (Mg2+) and Inorganic Phosphorus: Both ions are heavily concentrated within erythrocytes, causing significant false elevations in hemolyzed specimens.

Spectrophotometric and Chemical Interferences

Free oxyhemoglobin exhibits intense optical absorbance at its Soret band (~415 nm) with distinctive dual absorption peaks at 540 nm and 575 nm. This strong absorbance directly overlaps the reaction wavelengths used in numerous spectrophotometric assays, causing optical interference with bilirubin (diazo method), total protein (Biuret reaction), and certain alkaline phosphatase methods. Furthermore, free hemoglobin acts as a direct inhibitor or cross-reactant in high-sensitivity cardiac troponin immunoassays.

In Vivo Hemolysis vs. In Vitro Draw Trauma

2. Icterus

Icterus is the presence of elevated bilirubin concentrations in serum or plasma, imparting a bright yellow, amber, or green-brown discoloration. Visible icterus typically appears when total bilirubin exceeds 2.0 to 3.0 mg/dL (34 to 51 μmol/L).

Mechanisms of Interference

• Spectrophotometric Spectral Overlap: Bilirubin exhibits intense absorbance between 400 nm and 500 nm, with a peak near 450 nm. Assays that measure optical absorbance changes within this window experience baseline offset.
• Chemical Free-Radical Scavenging: Bilirubin is a potent natural antioxidant. In clinical chemistry, dozens of automated enzymatic assays rely on the Trinder reaction (coupled oxidase-peroxidase system generating hydrogen peroxide, which reacts with a chromogen like 4-aminophenazone to produce a colored dye). Bilirubin directly consumes and scavenges the intermediate hydrogen peroxide (H2O2) and free radical intermediates, severely depressing dye formation. This causes significant false negative bias in glucose (glucose oxidase), total cholesterol (cholesterol oxidase), triglycerides, and uric acid (uricase) assays.
• Kinetic Jaffe Creatinine Interference: In the alkaline picrate reaction for creatinine, bilirubin undergoes oxidation to biliverdin in the presence of strong alkali, producing a rapid decrease in absorbance at 500 nm that creates an artificial negative rate of reaction, causing severe false depression of measured creatinine.

3. Lipemia

Lipemia is defined as visible turbidity or milkiness in serum or plasma caused by light-scattering lipoprotein particles, predominantly large chylomicrons (diameter 75-1200 nm) and very-low-density lipoproteins (VLDL, diameter 30-80 nm). Visible turbidity generally emerges when serum triglycerides exceed 300 to 400 mg/dL (3.4 to 4.5 mmol/L).

Physical Light Scattering

Because chylomicron particles are larger than the wavelength of visible and ultraviolet light, they produce intense, non-specific light scattering (Tyndall effect) across the entire measuring spectrum (340 to 700 nm). This elevates baseline optical absorbance, producing significant analytical errors in end-point spectrophotometric assays such as total protein, albumin, hemoglobin, and lipase.

The Volume Displacement Effect (Electrolyte Exclusion Artifact)

Under normal physiological conditions, plasma is composed of approximately 93% aqueous solvent (water) and 7% non-aqueous solid phase (dissolved proteins and lipids). Electrolytes (sodium, potassium, chloride) are dissolved exclusively within the 93% aqueous phase.

• Indirect Ion-Selective Electrodes (Indirect ISE): Automated chemistry core analyzers utilize indirect ISEs. To conserve sample, the instrument performs a fixed pre-analytical dilution of the patient's specimen (e.g., 1:20 or 1:30 with an aqueous diluent) prior to presenting the specimen to the ionophore membrane. The instrument's calculation algorithm assumes that the original specimen was composed of 93% water.
• The Lipemic Dilution Artifact: In severe hyperlipidemia (triglycerides >1,500-3,000 mg/dL) or extreme paraproteinemia (multiple myeloma), the non-aqueous lipid/protein phase expands to occupy 20% to 30%+ of the total specimen volume, shrinking the aqueous solvent phase to 70% to 80%. When the automated instrument measures and dilutes the total specimen volume, it takes a fixed aliquot containing substantially less aqueous water and fewer actual sodium ions. The resulting calculated concentration is falsely low, producing profound pseudohyponatremia and pseudohypochloremia.
• Direct Ion-Selective Electrodes (Direct ISE): Blood gas analyzers and point-of-care (POC) devices measure the specimen neat (undiluted). The ion-selective electrode measures the true electrochemical thermodynamic activity of the electrolyte directly in the aqueous water phase, completely unaffected by the volume of circulating lipids or paraproteins. In cases of pseudohyponatremia from lipemia, the indirect ISE might report a panic sodium of 118 mmol/L, while the direct ISE on a blood gas analyzer reveals a normal true physiological sodium of 140 mmol/L.

+-----------------------------------------------------------------------------------------+
|               Volume Displacement (Electrolyte Exclusion) Mechanism                     |
+-----------------------------------------------------------------------------------------+
| Normal Specimen:           93% Aqueous Phase (Electrolytes)      │ 7% Solid (Lipid/Protein) |
|                            ══════════════════════════════════════│ ───────                  |
| Indirect ISE Calculation assumes 93% water ──> Accurately reflects physiological Na+    |
|                                                                                         |
| Grossly Lipemic Specimen:  70% Aqueous Phase (Electrolytes)      │ 30% Expanded Lipid Phase |
|                            ════════════════════════════          │ ════════════════════════ |
| Indirect ISE dilutes total volume ──> Measures less aqueous Na+ ──> PSEUDOHYPONATREMIA  |
| Direct ISE (undiluted) ─────────────> Measures aqueous phase directly ──> TRUE SODIUM   |
+-----------------------------------------------------------------------------------------+

Corrective Actions for Lipemia

1. High-Speed Ultracentrifugation: Centrifuging the specimen in an air-driven ultracentrifuge (Airfuge) at 100,000 × g for 10 to 15 minutes forces chylomicrons to form a floating creamy pellicle at the surface. The clear, non-lipemic infranatant is aspirated from beneath the lipid layer and analyzed for electrolytes, enzymes, and general chemistry analytes.
2. Critical Exception: Lipid and lipoprotein testing (triglycerides, cholesterol, HDL, Apo B) must never be performed on an ultracentrifuged cleared infranatant, as the clearing process physically removes the very analytes being measured!
3. Direct ISE Testing: Running the sample on an undiluted direct ISE (such as a whole blood gas analyzer) provides immediate, accurate electrolyte results without requiring ultracentrifugation.

---

Specimen Rejection Criteria and Mandatory Corrective Actions

Maintaining strict specimen acceptance criteria is a non-negotiable component of laboratory quality assurance under CAP, CLIA '88, and CLSI guidelines:

• Gross Hemolysis: Reject specimen and request an immediate redraw for potassium, LD, AST, magnesium, and cardiac troponin. If the physician insists on testing, report the result with a mandatory prominent laboratory narrative comment detailing the hemolysis index and clinical disclaimer.
• Gross Clotting in Anticoagulated Tubes: Inspect plasma and whole blood tubes for microclots prior to analysis. Fibrin clots consume clotting factors, trap platelets and cells, obstruct analyzer sample probes, and alter biochemical concentrations. Immediate rejection is mandatory.
• Quantity Not Sufficient (QNS): When insufficient sample volume is submitted, prioritizing testing based on clinical necessity or contacting the ordering provider is required. Never attempt to run automated testing below validated analyzer minimum dead volumes.
• Underfilled Sodium Citrate Tubes: Tubes filled to less than 90% of the nominal fill volume must be rejected due to excess free citrate altering the critical 9:1 ratio.
• Mislabeled or Unlabeled Tubes: Strict zero-tolerance policy. An unlabeled or mislabeled specimen must be rejected immediately; relabeling by laboratory staff is prohibited.

---

Reference Intervals and Clinical Consensus (CLSI EP28-A3c)

A Reference Interval (Reference Range) is statistically defined as the central 95% of test results obtained from an appropriately selected reference population presumed to be in good health. By mathematical definition, 5% of entirely healthy individuals will fall outside any single reference interval (2.5% below the lower limit and 2.5% above the upper limit).

                          Normal (Gaussian) Distribution
                                  Mean (μ)
                                     │
                                ┌────┴────┐
                                │         │
                           ┌────┘         └────┐
                        ┌──┘                   └──┐
                     ┌──┘                         └──┐
                  ┌──┘                               └──┐
            ──────┴─────────────────────────────────────┴──────
                 -2 SD                                 +2 SD
           [ 2.5% Below ]     [ Central 95% Interval ]    [ 2.5% Above ]
             Lower Limit                                   Upper Limit

Establishing vs. Verifying Reference Intervals

The CLSI guideline EP28-A3c (Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory), formerly numbered C28-A3c, establishes the international standard for laboratory reference ranges:

1. De Novo Direct Establishment: Establishing an original reference interval requires recruiting a minimum of 120 healthy reference individuals for each demographic partition (e.g., adult males, adult females, pediatric cohorts). This sample size (n >= 120) is mathematically required to calculate the 2.5th and 97.5th percentiles with acceptable 90% confidence intervals around the limits using non-parametric statistics.
2. Transference and Verification (Validation): Because recruiting 120 healthy subjects per partition is resource-prohibitive for routine clinical laboratories, CLSI permits transference of established reference intervals from reputable manufacturers, peer-reviewed literature, or multi-center consortia, provided the laboratory verifies the interval locally.
   • The 20-Subject Verification Protocol: The laboratory collects specimens from 20 qualified healthy reference individuals representing the local population.
   • Acceptance Criterion: If no more than 2 of the 20 results (<=10%) fall outside the proposed transferred interval, the reference range is statistically verified and adopted.
   • Remediation: If 3 or 4 individuals fall outside, an additional 20 reference individuals must be tested. If >10% continue to fall outside, the transferred interval is rejected, and a full de novo study (n >= 120) or method investigation must be conducted.

Parametric vs. Non-Parametric Estimation

• Parametric Estimation (Mean +/- 2 SD): Assumes the underlying analyte values conform strictly to a symmetrical, Gaussian (bell-shaped) normal distribution. The reference interval is calculated directly as Mean +/- 1.96 × SD (or +/- 2 × SD).
• Non-Parametric Estimation (Percentile Ranking): Makes no assumptions regarding the underlying distribution shape. All reference values are ranked in ascending numerical order, and the 2.5th percentile is designated the lower limit, while the 97.5th percentile is designated the upper limit. Non-parametric analysis is mandatory for biological analytes exhibiting skewed, non-Gaussian distributions, including serum enzymes (ALT, AST, ALP), bilirubin, cardiac troponin, and TSH.

---

The ASCP BOC Composite Reference Ranges Used on the Examination

Individual laboratories set their own reference intervals, but the examination does not. The ASCP BOC publishes a fixed set of composite reference ranges — reviewed annually by the Chemistry Examination Committee, inclusive of all genders and ethnic populations, and derived from published textbook sources — and states that all corresponding laboratory values on the examination can be interpreted using these ranges. Two facts make this table high-yield: the ranges are not supplied during the examination (other ranges are provided as needed), and laboratory results and reference ranges appear on the examination in both conventional and SI units.

Several additional ranges — total cholesterol < 200 mg/dL, triglycerides < 150 mg/dL, HDL cholesterol > 40 mg/dL, LDL cholesterol < 100 mg/dL, total protein 6.0 - 8.0 g/dL, calcium 8.6 - 10.2 mg/dL, total bilirubin 0.2 - 1.2 mg/dL, direct/conjugated bilirubin < 0.2 mg/dL, and indirect/unconjugated bilirubin 0.3 - 1.0 mg/dL — are published by the BOC for the SC (Specialist in Chemistry) examination only. They remain excellent working values to memorize for clinical reasoning, but on the C examination those ranges will be supplied with the item if they are needed.

[!WARNING] Watch the small discrepancies between the BOC composite table and the generic textbook intervals used elsewhere in this guide and in most hospitals: BOC sodium is 136 - 145 (not 135 - 145), potassium is 3.5 - 5.1 (not 3.5 - 5.0), arterial pCO2 tops out at 44 mm Hg (not 45), and total CO2 (22 - 33 mmol/L) is deliberately a wider interval than measured bicarbonate (23 - 29 mmol/L) because total CO2 also includes dissolved CO2 and carbamino compounds. On the examination, classify a value against the BOC range; in the laboratory, classify it against your own validated interval. These reference ranges are for examination purposes only and are not intended for clinical application.

---

Critical Values (Panic Values) and Patient Safety Protocols

A Critical Value (commonly termed a "Panic Value") is defined as an analytical laboratory test result that represents a life-threatening or immediately dangerous pathophysiological state. If immediate clinical corrective action is not instituted, the patient faces imminent risk of morbidity or mortality.

Regulatory Mandates and Notification Protocols

Under CLIA '88 regulations, the College of American Pathologists (CAP) accreditation standards, and The Joint Commission National Patient Safety Goals (NPSG Goal 2: Improve the accuracy of patient identification and clinical communication):

1. Immediate Direct Notification: The clinical laboratory must notify a licensed independent practitioner (or their designated clinical care team member responsible for the patient) immediately upon obtaining and verifying a critical result, typically within a strict mandatory turnaround time of <15 to 30 minutes from result generation.
2. Read-Back Verification (Closed-Loop Communication): The technologist cannot merely state the result. The recipient must read back the complete result verbatim, including:
   • Two distinct patient identifiers (patient full legal name and Medical Record Number or Date of Birth)
   • The specific test name
   • The exact numerical result and units of measure
3. Comprehensive Legal Documentation: Every critical value call must be logged in the Laboratory Information System (LIS) with complete audit trail data:
   • Date and exact time of notification
   • Full legal name and clinical credential of the individual receiving the notification
   • Name and initials of the reporting medical technologist
   • Explicit electronic checkbox or entry confirming that "read-back was requested, completed, and verified accurate"
   • Number of call attempts made if initial communication was unsuccessful, escalating to nursing supervisors or on-call medical directors according to laboratory policy

Representative Clinical Chemistry Critical Limits

---

Delta Checks in Clinical Quality Assurance

A Delta Check is an automated quality control algorithm embedded within the Laboratory Information System that mathematically compares a patient's current analytical result with their most recent previous result for the same analyte within a specified time interval (e.g., within 24 to 72 hours).

Purpose and Detective Capability

If the absolute or percentage difference between the two consecutive results exceeds a pre-set threshold (the "delta limit"), the LIS flags the result and holds it from automated verification. Delta checks are uniquely sensitive tools for detecting:

1. Pre-Analytical Specimen Misidentification ("Wrong Blood in Tube"): If a patient's creatinine abruptly shifts from 0.8 mg/dL to 4.5 mg/dL in 4 hours, or blood group/hemoglobin values demonstrate impossible shifts, specimen mislabeling is suspected.
2. Intravenous Fluid Contamination: A blood sample drawn above an active IV infusion line (e.g., 5% Dextrose in Water [D5W] or 0.9% Normal Saline) results in hemodilution. An IV saline contamination produces an abrupt spike in sodium and chloride accompanied by a dramatic, uniform drop in all other chemistry analytes (potassium, calcium, BUN, creatinine, total protein). An IV dextrose contamination produces a massive, physiologically impossible spike in glucose (e.g., >1,200 mg/dL) with dilution of electrolytes.
3. Acute In Vitro Hemolysis During Phlebotomy: A sudden spike in potassium or LD compared to a baseline drawn 6 hours earlier alerts the technologist to inspect the serum tube for in vitro draw trauma.
4. True Acute Clinical Deterioration: A valid delta check failure may reflect catastrophic physiological changes, such as acute upper gastrointestinal hemorrhage (sharp hemoglobin drop with rising BUN), acute renal failure (rapidly escalating BUN and creatinine), or acute rhabdomyolysis (exponential CK surge).

Technologist Investigation of a Delta Flag

When a delta check triggers, the technologist must execute a standardized investigative sequence:

1. Inspect the physical specimen for hemolysis, icterus, lipemia, fibrin microclots, or inadequate sample volume.
2. Review the patient's electronic medical record: did the patient undergo dialysis, receive blood products, or undergo surgical intervention?
3. Re-run the specimen to rule out analyzer pipetting errors or bubbles.
4. Check historical results and other concurrent laboratory departments (e.g., compare chemistry tube against hematology CBC tube for matching MCV and blood typing).
5. If specimen misidentification or IV contamination is confirmed or suspected, cancel the result, document the investigation, and request an immediate redrawn specimen.

---

Comprehensive Summary Table of Interferences and Remediation